Prime medicine to highlight positive preclinical developments across prime editing pipeline and platform at upcoming industry conferences

Cambridge, mass., oct. 17, 2023 (globe newswire) -- prime medicine, inc. (nasdaq: prme), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the company will showcase advances in preclinical data across the prime editing pipeline and platform at several healthcare industry conferences in october and november 2023.
PRME Ratings Summary
PRME Quant Ranking